Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH. N Engl J Med. 2017 Dec 10. doi: 10.1056/NEJMoa1708566. [Epub ahead of print]
Summary
Global CAR T Therapy Trial Shows High Rates of Durable Remission for Non-Hodgkin’s Lymphoma: Additional data shows remissions past two years among patients treated in earlier pilot study.
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin’s lymphoma (NHL) patients. Results from a global, multisite trial were presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta (Abstract #577). Results from the single-site study, with follow-up extending past two years, will be published in the New England Journal of Medicine.
Read the Department of Communications news release
